What can we help you find? Enter your search above.
What can we help you find? Enter your search above.
Communicating with Sugarman Rogers through this website does not create an attorney-client relationship with the firm or any of our attorneys. Our decision as to whether and on what terms we may agree to represent a client involves consideration of a variety of factors, discussion with the prospective client, and, where appropriate, a written engagement agreement.
Please do not use this form of communication to transmit any private, personally identifying, or other confidential information. We cannot guarantee the confidentiality or security of this means of communication.
Susan Broh, a previously healthy 57 year-old woman, died in September 2001 of massive liver failure caused by Serzone, an anti-depressant manufactured and sold by Bristol-Myers Squibb, which she had begun taking less than three months earlier for mild depression, on the advice and prescription of a psychiatrist. Shortly after Susan began taking Serzone, BMS sent a letter to doctors in Canada, warning them about reports of severe liver injury associated with use of the drug, and recommending that a number of precautions be followed whenever it was prescribed. BMS provided similar warnings in other countries at the behest of local regulators, but failed to give the same information to doctors in the United States until several months after Susan’s death, when the company was ordered by the FDA to place a “black-box” warning on the label for Serzone. Susan was unmarried at the time of her death, and had no children. Sugarman Rogers was retained to represent her estate, and brought suit against BMS in New York. In 2005, BMS entered into an agreement to settle Serzone cases nationwide, including this matter, which settled for $2.9 million.
|
|
Favorable settlement of pharmaceutical case |
Date: September 1, 2024 |
Case Report |
Michael S. Appel |
Related Services: Defective Drugs & Medical Devices |
||
|
Susan Broh, a previously healthy 57 year-old woman, died in September 2001 of massive liver failure caused by Serzone, an anti-depressant manufactured and sold by Bristol-Myers Squibb, which she had begun taking less than three months earlier for mild depression, on the advice and prescription of a psychiatrist. Shortly after Susan began taking Serzone, BMS sent a letter to doctors in Canada, warning them about reports of severe liver injury associated with use of the drug, and recommending that a number of precautions be followed whenever it was prescribed. BMS provided similar warnings in other countries at the behest of local regulators, but failed to give the same information to doctors in the United States until several months after Susan’s death, when the company was ordered by the FDA to place a “black-box” warning on the label for Serzone. Susan was unmarried at the time of her death, and had no children. Sugarman Rogers was retained to represent her estate, and brought suit against BMS in New York. In 2005, BMS entered into an agreement to settle Serzone cases nationwide, including this matter, which settled for $2.9 million. |
Related People |
|||
Michael S. AppelOf Counsel617.227.3030[email protected] |
|||